Day One Biopharmaceuticals I (DAWN) Technical Analysis
$21.32▲0.24%
Market is closed - opens 7 PM, 16 Mar 2026
Insights
- Day One Biopharmaceuticals I is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Day One Biopharmaceuticals I stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Day One Biopharmaceuticals I stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Day One Biopharmaceuticals I stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 82.57 | Sell |
Stochastic | 98.95, 98.66 | Neutral |
Ultimate Oscillator | 84.51 | Sell |
Stochastic Relative Strength Index | 98.9, 99.08 | Sell |
Moving Average Convergence Divergence | 2.71, 1.68 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 17.37 | Buy |
20 | 14.41 | Buy |
50 | 12.25 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 18.35 | Buy |
20 | 15.85 | Buy |
50 | 13.03 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 19.93 | Buy |
20 | 18.83 | Buy |
50 | 16.21 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 21.61 | Buy |
20 | 19.1 | Buy |
50 | 15.79 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 22.77 | Buy |
20 | 21.03 | Buy |
50 | 17.33 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 21.36 |
Resistance L2 | 21.33 |
Resistance L1 | 21.3 |
Pivot Point | 21.27 |
Support L1 | 21.24 |
Support L2 | 21.21 |
Support L3 | 21.18 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.